MT1M and MT1G Promoter Methylation As Biomarkers for Hepatocellular Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 May 1

PMID 24782625

Citations 49

Authors

Xiang-Fen Ji

Yu-Chen Fan

Shuai Gao

Yang Yang

Jian-Jun Zhang

Kai Wang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the potential of promoter methylation of two tumor suppressor genes (TSGs) as biomarkers for hepatocellular carcinoma (HCC).

Methods: A total of 189 subjects were included in this retrospective cohort, which contained 121 HCC patients without any history of curative treatment, 37 patients with chronic hepatitis B (CHB), and 31 normal controls (NCs). DNA samples were extracted from 400 μL of serum of each subject and then modified using bisulfite treatment. Methylation of the promoters of the TSGs (metallothionein 1M, MT1M; and metallothionein 1G, MT1G) was determined using methylation-specific polymerase chain reaction. The diagnostic value of combined MT1M and MT1G promoter methylation was evaluated using the area under the receiver operating characteristic curves.

Results: Our results indicated that the methylation status of serum MT1M (48.8%, 59/121) and MT1G (70.2%, 85/121) promoters in the HCC group was significantly higher than that in the CHB group (MT1M 5.4%, 2/37, P < 0.001; MT1G 16.2%, 6/37, P < 0.001) and NC group (MT1M 6.5%, 2/31, P < 0.001; MT1G 12.9%, 4/27, P < 0.001). Aberrant serum MT1M promoter methylation gave higher specificity to discriminate HCC from CHB (94.6%) and NCs (93.5%), whereas combined methylation of serum MT1M and MT1G promoters showed higher diagnostic sensitivity (90.9%), suggesting that they are potential markers for noninvasive detection of HCC. Furthermore, MT1M promoter methylation was positively correlated with tumor size (rs = 0.321, P < 0.001), and HCC patients with both MT1M and MT1G promoter methylation tended to show a higher incidence of vascular invasion or metastasis (P = 0.018).

Conclusion: MT1M and MT1G promoter methylation may be used as serum biomarkers for noninvasive detection of HCC.

Citing Articles

Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.

Su L, Bu J, Yu J, Jin M, Meng G, Zhu X Clin Transl Med. 2024; 14(11):e70066.

PMID: 39462685 PMC: 11513202. DOI: 10.1002/ctm2.70066.

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.

Chan Y, Zhang C, Wu J, Lu P, Xu L, Yuan H Mol Cancer. 2024; 23(1):189.

PMID: 39242496 PMC: 11378508. DOI: 10.1186/s12943-024-02101-z.

Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers.

Mishra M, Ahmed R, Das D, Pramanik D, Dash S, Pramanik A ACS Biomater Sci Eng. 2024; 10(8):4740-4756.

PMID: 38950521 PMC: 11322919. DOI: 10.1021/acsbiomaterials.4c00606.

Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells.

Rodrigo M, Michalkova H, Jimenez A, Petrlak F, Do T, Sivak L Biomark Res. 2024; 12(1):38.

PMID: 38594765 PMC: 11003176. DOI: 10.1186/s40364-024-00584-y.

Detection of hepatocellular carcinoma methylation markers in salivary DNA.

Mezzacappa C, Wang Z, Lu L, Risch H, Taddei T, Yu H Biosci Rep. 2024; 44(3).

PMID: 38457142 PMC: 10958141. DOI: 10.1042/BSR20232063.

References

Yeo W, Wong N, Wong W, Lai P, Zhong S, Johnson P . High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005; 25(2):266-72. DOI: 10.1111/j.1478-3231.2005.01084.x. View

Cai L, Satoh M, Tohyama C, Cherian M . Metallothionein in radiation exposure: its induction and protective role. Toxicology. 1999; 132(2-3):85-98. DOI: 10.1016/s0300-483x(98)00150-4. View

Zhang Y, Wu H, Shen J, Ahsan H, Tsai W, Yang H . Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007; 13(8):2378-84. DOI: 10.1158/1078-0432.CCR-06-1900. View

Tao X, Zheng J, Xu A, Chen X, Zhang S . Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res. 2007; 37(10):820-7. DOI: 10.1111/j.1872-034X.2007.00113.x. View

Ye Q, Qin L, Forgues M, He P, Kim J, Peng A . Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003; 9(4):416-23. DOI: 10.1038/nm843. View

Garrett S, Sens M, Shukla D, Flores L, Somji S, Todd J . Metallothionein isoform 1 and 2 gene expression in the human prostate: downregulation of MT-1X in advanced prostate cancer. Prostate. 2001; 43(2):125-35. DOI: 10.1002/(sici)1097-0045(20000501)43:2<125::aid-pros7>3.0.co;2-s. View

Wang J, Qin Y, Li B, Sun Z, Yang B . Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem. 2006; 39(4):344-8. DOI: 10.1016/j.clinbiochem.2006.01.008. View

Baba H, Grabellus F, August C, Plenz G, Takeda A, Tjan T . Reversal of metallothionein expression is different throughout the human myocardium after prolonged left-ventricular mechanical support. J Heart Lung Transplant. 2000; 19(7):668-74. DOI: 10.1016/s1053-2498(00)00074-7. View

Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C . Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol. 2006; 101(3):524-32. DOI: 10.1111/j.1572-0241.2006.00443.x. View

10.

Babula P, Masarik M, Adam V, Eckschlager T, Stiborova M, Trnkova L . Mammalian metallothioneins: properties and functions. Metallomics. 2012; 4(8):739-50. DOI: 10.1039/c2mt20081c. View

11.

Wong I, Lo Y, Yeo W, Lau W, Johnson P . Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res. 2000; 6(9):3516-21. View

12.

Mao J, Yu H, Wang C, Sun L, Jiang W, Zhang P . Metallothionein MT1M is a tumor suppressor of human hepatocellular carcinomas. Carcinogenesis. 2012; 33(12):2568-77. DOI: 10.1093/carcin/bgs287. View

13.

Mohamed N, Swify E, Amin N, Soliman M, Tag-Eldin L, Elsherbiny N . Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?. Arab J Gastroenterol. 2012; 13(3):111-5. DOI: 10.1016/j.ajg.2012.06.009. View

14.

Srivatanakul P, Sriplung H, Deerasamee S . Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev. 2004; 5(2):118-25. View

15.

Henrique R, Jeronimo C, Hoque M, Nomoto S, Carvalho A, Costa V . MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(5):1274-8. DOI: 10.1158/1055-9965.EPI-04-0659. View

16.

Zhu J . DNA methylation and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2006; 13(4):265-73. DOI: 10.1007/s00534-005-1054-4. View

17.

Zhang L, Zhou W, Velculescu V, Kern S, Hruban R, Hamilton S . Gene expression profiles in normal and cancer cells. Science. 1997; 276(5316):1268-72. DOI: 10.1126/science.276.5316.1268. View

18.

Chung J, Lee H, Kim B, Cho N, Kang G . DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch. 2011; 459(2):201-11. DOI: 10.1007/s00428-011-1079-9. View

19.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

20.

Cai L, Wang G, Xu Z, Deng D, Chakrabarti S, Cherian M . Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. Anticancer Res. 1999; 18(6B):4667-72. View